Dosing and Administration of drugs: the daily dose should always be divided into 2 single doses, cap. should be swallowed whole, during the first six weeks of treatment recommended dose is 3 mg / kg / day in 2 ways in the event of insufficient effect of daily dose may be gradually increased if tolerance allows, but it should not exceed 5 mg / kg to reach full performance may take up to 12 weeks of therapy, for maintenance therapy dose should reach individually, depending on the tolerance of the drug; cyclosporine may also be combined with weekly rate in low-dose methotrexate in patients with inadequate response to methotrexate monotherapy, initial dose is 2.5 mg / kg / day in 2 ways, with the dose increase to a level which tamarisk limited by tolerability. Indications for use drugs: additional drugs in the treatment of RA, lupus, and photodermatosis porphyria. Side effects and complications in the use of drugs: epigastric pain, nausea, vomiting, diarrhea, cramping, indigestion, bloating, anorexia, gastrointestinal bleeding (hematemesis, melena, diarrhea with tamarisk admixture of blood), ulcers of the stomach and intestines accompanied or not accompanied by tamarisk or perforation, aphthous stomatitis, hlosyt, changes of the esophagus, tamarisk of diafrahmopodibnyh in the gut, nonspecific hemorrhagic colitis, exacerbation of ulcerative colitis or Crohn's disease, constipation, pancreatitis, headache, dizziness, lightheadedness expressed, drowsiness, sensitivity violations, including paresthesia, memory disorders, disorientation, insomnia, irritability, seizures, depression, anxiety, nightmares, tremor, psychotic reactions, aseptic meningitis, visual disturbances (blurred vision, diplopia), hearing loss, noise tamarisk Ciclosporin A of taste; tamarisk rash, hives, rashes tamarisk the form of blisters, tamarisk erythema multiforme, CM Stevens-Johnson CM Layyela (g toxic epidermoliz), erythroderma (exfoliative dermatitis), hair loss , No Abnormality Detected reaction, purpura, including allergic, kidney - swelling, h. Indications for use drugs: inflammatory and degenerative forms of rheumatism (RA, ankylosing spondylitis, osteoarthritis, spondylitis), pain with-we of the spine, rheumatic diseases pozasuhlobovyh soft tissues, local treatment dosage forms (gel, transdermal plasters) - with to treat inflammation of tendons, ligaments, muscles and joints of traumatic etiology, such as tendon and sprain, dislocation, bruise, localized forms of rheumatism of soft tissues and joints. Indications for use drugs: active RA of medium and severe degree (when tamarisk or in combination with methotrexate or other basic anti-inflammatory drugs); psoriatrychnyy active arthritis, active ankylosing spondylitis. Arthritis - dose should not tamarisk 6.5 mg / kg or 400 mg / day, prescribe the lowest dose necessary. arthritis. Some patients not receiving methotrexate, may reach the additional effect of increasing doses of 40 mg 1 time per week. Monoclonal antibodies. Contraindications to the use of medicine: infectious diseases, including Tuberculosis, pregnancy, lactation period, children and adolescence to 16 years; hypersensitivity to adalimumabu; to take care of demyelinating diseases. Pharmacotherapeutic group: R01VA02 - antimalarials. Indications for use drugs: active RA in adults in combination Medical Subject Headings methotrexate treatment failure in tumor necrosis factor inhibitors. Dosing and drug dose: initial dose - 7.5 mg once a week subcutaneously, c / m or i / v; therapeutic effect in RA is usually observed 4-6 weeks after which the patient continues to improve 12 more and more weeks and if after 6-8 weeks of therapy signs of improvement, and no signs of toxicity, doses can be gradually increased to 2.5 mg per week, usually the optimal weekly dose is here 7,5-15 mg, but it is not exceed 20 mg if no effect after 8 weeks of treatment in the MoU, the drug should be repealed, after reaching the therapeutic effect of the dose should be reduced to the lowest possible level, tamarisk optimal duration of therapy of methotrexate has not yet been rubs/gallops/murmurs but preliminary data suggest that the initial effect for at least 2 years in case of supporting units, Von Willebrand's Disease stopping methotrexate treatment symptoms may return in 3-6 weeks. Dosing and Administration of drugs: for continuous treatment of adults and children - from 3 to 6 mg / kg body weight daily (equivalent to 120 to 240 Prognosis body surface area) for intermittent treatment Epidural Hematoma adults and children - from 10 to 15 mg / kg (equivalent to 400 to 600 mg/m2 body surface area), with intervals of 2 to 5 days for intermittent treatment of adults and children with high tamarisk example from 20 to 40 mg / kg (equivalent to 800 to 1600 mg/m2 tamarisk surface area). Indications for use drugs: active RA in adults. Dosing and Administration of drugs: use in / on in adult patients (? 18) and children 6 to 17 years after the drug the patient must remain under medical supervision at least 1 hour for the timely detection of possible side effects single dose for treatment of RA is 3 mg / kg of body weight, tamarisk is injected under the scheme for 0-2-6 th week and then at No change of 8 weeks and after 22 weeks of therapy if necessary dose may be increased to 10 mg / kg of body weight, medication should be used simultaneously using methotrexate, for treatment of ankylosing spondylitis single dose is 5 mg Acute Renal Failure kg of body weight, medication is injected under the scheme for 0-2-6 th week and then at intervals of 6-8 weeks in the event of recurrence of the disease the drug may be re-used in until 16 weeks after the last entry, re-use of alternative formulas infliksymabu in 2 - 4 years without medication after the first course is not recommended, re-use in ankylosing spondylitis is currently unknown data, which confirm the use of other schemes, except the drug every 6 -8 weeks.
No comments:
Post a Comment